A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleuc
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).
| Condition(s) | Multiple Myeloma |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM). |
| Who can participate | Inclusion Criteria: * History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2). * Measurable multiple myeloma (MM) as per International Myeloma Working Group (IMWG). * Eastern Cooperative Oncology Group performance status of 0-1. Exclusion Criteria: * Prior treatment with alnuctamab (Arm A), mezigdomide (Arm B), iberdomide (Arm C), elranatamab (Arm D) or BCMA-targeting therapy (Part 2 Arms A and D). * Prior treatment with GPRC5D-targeting therapies. * Other protocol-defined inclusion/exclusion criteria apply. |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
| Locations | Birmingham, Alabama, United States; Phoenix, Arizona, United States; Duarte, California, United States; Jacksonville, Florida, United States; Atlanta, Georgia, United States; Boston, Massachusetts, United States (+13 more sites) |
| Start date | 2024-02-22 |
| NCT ID | NCT06121843 |
| Official listing | https://clinicaltrials.gov/study/NCT06121843 |